Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Merkel Cell Polyomavirus specific TCR redirected T-cell therapy - bluebird bio/Fred Hutchinson Cancer Research Center

Next Previous
Search
Drug Profile

Merkel Cell Polyomavirus specific TCR redirected T-cell therapy - bluebird bio/Fred Hutchinson Cancer Research Center

Alternative Names: (MCPyV) TCR-engineered autologous T cells - bluebird bio/Fred Hutchinson Cancer Research Center; Autologous TCR redirected T-cell therapy - bluebird bio/Fred Hutchinson Cancer Research Center; FH-MCVA2TCR; FH-MCVA2TCR T-cells; MCC1 TCR; Merkel Cell Polyomavirus TCR-engineered autologous T cells - bluebird bio/Fred Hutchinson Cancer Research Center

Latest Information Update: 08 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator bluebird bio; Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Merkel cell carcinoma

Most Recent Events

  • 25 Oct 2024 Fred Hutchinson Cancer Research Center terminates a phase I/II trial in Merkel cell carcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) due to insufficient funding (NCT03747484)
  • 01 May 2020 Bluebird Bio and Fred Hutchinson Cancer Research Center reinitiates phase I/II trial in Merkel cell carcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT03747484)
  • 30 Mar 2020 Bluebird Bio and Fred Hutchinson Cancer Research Center suspends phase I/II trial in Merkel cell carcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA, due to COVID-2019 pandemic (IV) (NCT03747484)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top